Strategy decision
Loading the recorded decision…
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Using this strategy in your portfolio? Open the Builder to review its source targets. Review your saved portfolio →
The decision
I retain 3,500 basis points of cash, leaving exactly 6,500 for 21 equities. This book favors inexpensive reported profits over promotional forecasts, while preserving existing sleeves where today's evidence does not establish a changed thesis. Missing receivables, cash-flow reconciliation and debt-maturity schedules remain open files—not evidence of clean earnings. ABM moves modestly from 2.77% currently and the recent 2.80% target to 2.60% because October 13 commentary identifies rising borrowings and interest expense. The largest allocation is 4.40%, below the mandate's 5% ceiling; ADMA and HRMY together remain capped at 6%.
Targets & reasoning
Before is the portfolio weight captured at decision time. Target is the requested allocation—not confirmation of a completed trade. These are simulated strategy weights, not personalized allocations.
| Stock / cash | Before | Target | Change | Reason |
|---|---|---|---|---|
| Cash · USDIncrease target | 34.82% | 35% | +0.18 pp | No holding-specific reason was recorded. |
| ZDReduce target | 4.52% | 4.4% | -0.12 pp | I expect ZD's $18.29 EPS at a 3.16 multiple to offer the book's deepest reported earnings discount.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect ZD's $18.29 EPS at a 3.16 multiple to offer the book's deepest reported earnings discount. The 2.25% twenty-session decline does not settle whether that denominator is repeatable. What would change the view: I'm wrong if later filings expose one-off profits or weak cash realization; missing reconciliation keeps even this largest part of the portfolio below 5%. Original explanation and evidence referencesI expect ZD's $18.29 EPS at a 3.16 multiple to offer the book's deepest reported earnings discount [ZD-E3]. The 2.25% twenty-session decline does not settle whether that denominator is repeatable [ZD-E5]. I'm wrong if later filings expose one-off profits or weak cash realization; missing reconciliation keeps even this largest sleeve below 5%. |
| ASOReduce target | 4.12% | 4% | -0.12 pp | I expect ASO's $5.87 EPS at 9.35 times earnings to provide a useful valuation cushion.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect ASO's $5.87 EPS at 9.35 times earnings to provide a useful valuation cushion. The 8.84% twenty-session gain supplies secondary confirmation without replacing the profit ledger. What would change the view: I'm wrong if subsequent reports reveal deteriorating earnings or inventory-related cash pressure; I hold the part of the portfolio at 4%, not the maximum. Original explanation and evidence referencesI expect ASO's $5.87 EPS at 9.35 times earnings to provide a useful valuation cushion [ASO-E4]. The 8.84% twenty-session gain supplies secondary confirmation without replacing the profit ledger [ASO-E6]. I'm wrong if subsequent reports reveal deteriorating earnings or inventory-related cash pressure; I hold the sleeve at 4%, not the maximum. |
| INSWIncrease target | 3.97% | 4% | +0.03 pp | I expect INSW's $14.33 EPS at 8.73 times earnings to support continued value realization.Hide full reasonI expect INSW's $14.33 EPS at 8.73 times earnings to support continued value realization. October 13 commentary reports $935 million liquidity alongside $244 million carrier orders, a useful funding cross-check. What would change the view: I'm wrong if commitments consume liquidity faster than operations replenish it; trailing distributions are not a perpetual coupon. Original explanation and evidence referencesI expect INSW's $14.33 EPS at 8.73 times earnings to support continued value realization [INSW-E4]. October 13 commentary reports $935 million liquidity alongside $244 million carrier orders, a useful funding cross-check [INSW-E6]. I'm wrong if commitments consume liquidity faster than operations replenish it; trailing distributions are not a perpetual coupon. |
| PARRIncrease target | 3.88% | 3.9% | +0.02 pp | I expect PARR's $16.78 EPS at only 5.36 times earnings to leave substantial room for value realization.Hide full reasonI expect PARR's $16.78 EPS at only 5.36 times earnings to leave substantial room for value realization. Its 7.51% twenty-session advance corroborates the ledger without proving earnings quality. What would change the view: I'm wrong if later filings expose transient profits or cash-conversion weakness; projected growth headlines do not justify breaching my position cap. Original explanation and evidence referencesI expect PARR's $16.78 EPS at only 5.36 times earnings to leave substantial room for value realization [PARR-E3]. Its 7.51% twenty-session advance corroborates the ledger without proving earnings quality [PARR-E6]. I'm wrong if later filings expose transient profits or cash-conversion weakness; projected growth headlines do not justify breaching my position cap. |
| TDCReduce target | 3.91% | 3.9% | -0.01 pp | I expect TDC's $4.46 EPS at 6.83 times earnings to provide room for a valuation recovery.Hide full reasonI expect TDC's $4.46 EPS at 6.83 times earnings to provide room for a valuation recovery. Its 3.71% twenty-session advance gives restrained confirmation rather than a momentum mandate. What would change the view: I'm wrong if subsequent filings reveal nonrecurring earnings or deteriorating cash conversion; the low multiple earns attention, not immunity from accounting scrutiny. Original explanation and evidence referencesI expect TDC's $4.46 EPS at 6.83 times earnings to provide room for a valuation recovery [TDC-E3]. Its 3.71% twenty-session advance gives restrained confirmation rather than a momentum mandate [TDC-E5]. I'm wrong if subsequent filings reveal nonrecurring earnings or deteriorating cash conversion; the low multiple earns attention, not immunity from accounting scrutiny. |
| LPGReduce target | 3.83% | 3.8% | -0.03 pp | I expect LPG's $7.55 EPS at a 7.68 multiple to support earnings-backed appreciation.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect LPG's $7.55 EPS at a 7.68 multiple to support earnings-backed appreciation. Four recorded payments produce a 5.78% trailing yield, a cash trail rather than a forward commitment. What would change the view: I'm wrong if later statements show shrinking profits or distributions unsupported by cash; I retain a sub-4% part of the portfolio. Original explanation and evidence referencesI expect LPG's $7.55 EPS at a 7.68 multiple to support earnings-backed appreciation [LPG-E4]. Four recorded payments produce a 5.78% trailing yield, a cash trail rather than a forward commitment [LPG-E3]. I'm wrong if later statements show shrinking profits or distributions unsupported by cash; I retain a sub-4% sleeve. |
| LRNIncrease target | 3.46% | 3.5% | +0.04 pp | I expect LRN's $7.47 EPS at 11.11 times earnings to support patient appreciation.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect LRN's $7.47 EPS at 11.11 times earnings to support patient appreciation. That fundamental file is dated April 29, so October's nearly flat twenty-session return cannot refresh its accounting substance. What would change the view: I'm wrong if newer filings undermine the profit base; I retain exposure without awarding stale earnings a larger part of the portfolio. Original explanation and evidence referencesI expect LRN's $7.47 EPS at 11.11 times earnings to support patient appreciation [LRN-E3]. That fundamental file is dated April 29, so October's nearly flat twenty-session return cannot refresh its accounting substance [LRN-E5]. I'm wrong if newer filings undermine the profit base; I retain exposure without awarding stale earnings a larger sleeve. |
| ABCBReduce target | 3.2% | 3.2% | 0 pp | I expect ABCB's $5.54 of reported EPS at 14.25 times earnings to support measured appreciation.Hide full reasonI expect ABCB's $5.54 of reported EPS at 14.25 times earnings to support measured appreciation. The 1.01% dividend supplies a separate cash receipt, not a loan-quality certificate. What would change the view: I'm wrong if subsequent disclosures reveal credit costs consuming the earnings base; absent that ledger detail, I keep sizing restrained. Original explanation and evidence referencesI expect ABCB's $5.54 of reported EPS at 14.25 times earnings to support measured appreciation [ABCB-E4]. The 1.01% dividend supplies a separate cash receipt [ABCB-E3], not a loan-quality certificate. I'm wrong if subsequent disclosures reveal credit costs consuming the earnings base; absent that ledger detail, I keep sizing restrained. |
| ABGReduce target | 3.2% | 3.2% | 0 pp | I expect ABG's 5.24 multiple on $31.40 of EPS to leave room for earnings-led recovery.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect ABG's 5.24 multiple on $31.40 of EPS to leave room for earnings-led recovery. The 19.80% twenty-session decline is an unresolved clue, not a bargain certificate. What would change the view: I'm wrong if later filings show those profits cannot recur; I retain a contained part of the portfolio rather than average down aggressively. Original explanation and evidence referencesI expect ABG's 5.24 multiple on $31.40 of EPS to leave room for earnings-led recovery [ABG-E3]. The 19.80% twenty-session decline is an unresolved clue, not a bargain certificate [ABG-E5]. I'm wrong if later filings show those profits cannot recur; I retain a contained sleeve rather than average down aggressively. |
| ACAIncrease target | 3.02% | 3.1% | +0.08 pp | I expect ACA's $10.14 EPS at a 14.52 multiple to provide a workable foundation for patient appreciation.Hide full reasonI expect ACA's $10.14 EPS at a 14.52 multiple to provide a workable foundation for patient appreciation. Its 1.45% twenty-session gain is quiet corroboration, not the substance of my case. What would change the view: I'm wrong if subsequent filings expose nonrecurring profits or weaker cash conversion beneath that reported earnings line. Original explanation and evidence referencesI expect ACA's $10.14 EPS at a 14.52 multiple to provide a workable foundation for patient appreciation [ACA-E4]. Its 1.45% twenty-session gain is quiet corroboration, not the substance of my case [ACA-E6]. I'm wrong if subsequent filings expose nonrecurring profits or weaker cash conversion beneath that reported earnings line. |
| CACCIncrease target | 3.06% | 3.1% | +0.04 pp | I expect CACC to recover value if $41.91 of reported EPS remains durable at a 13.03 multiple.Hide full reasonI expect CACC to recover value if $41.91 of reported EPS remains durable at a 13.03 multiple. Its 9.02% twenty-session decline argues against enlarging this credit file. What would change the view: I'm wrong if collection performance or financing costs undermine those earnings; missing receivables detail prevents a stronger conviction stamp. Original explanation and evidence referencesI expect CACC to recover value if $41.91 of reported EPS remains durable at a 13.03 multiple [CACC-E3]. Its 9.02% twenty-session decline argues against enlarging this credit file [CACC-E5]. I'm wrong if collection performance or financing costs undermine those earnings; missing receivables detail prevents a stronger conviction stamp. |
| ADMAReduce target | 3.01% | 3% | -0.01 pp | I expect ADMA's positive $0.64 EPS at 16.11 times earnings to anchor returns in profits rather than excitement.Hide full reasonI expect ADMA's positive $0.64 EPS at 16.11 times earnings to anchor returns in profits rather than excitement. The 19.74% twenty-session advance confirms interest but earns no larger allocation. What would change the view: I'm wrong if later statements fail to sustain profitability; this biological-products file stays capped at 3%. Original explanation and evidence referencesI expect ADMA's positive $0.64 EPS at 16.11 times earnings to anchor returns in profits rather than excitement [ADMA-E3]. The 19.74% twenty-session advance confirms interest but earns no larger allocation [ADMA-E5]. I'm wrong if later statements fail to sustain profitability; this biological-products file stays capped at 3%. |
| HRMYReduce target | 3.04% | 3% | -0.04 pp | I expect HRMY's $3.38 EPS at a 10.96 multiple to leave room for valuation recovery.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect HRMY's $3.38 EPS at a 10.96 multiple to leave room for valuation recovery. The 12.19% twenty-session loss is adverse evidence that keeps this pharmaceutical part of the portfolio capped. What would change the view: I'm wrong if subsequent filings weaken the recurring profit base; I rely on earnings, not the supplied pipeline headline. Original explanation and evidence referencesI expect HRMY's $3.38 EPS at a 10.96 multiple to leave room for valuation recovery [HRMY-E3]. The 12.19% twenty-session loss is adverse evidence that keeps this pharmaceutical sleeve capped [HRMY-E6]. I'm wrong if subsequent filings weaken the recurring profit base; I rely on earnings, not the supplied pipeline headline. |
| PLABIncrease target | 2.73% | 2.8% | +0.07 pp | I expect PLAB's $2.16 EPS at 13.48 times earnings to offer a reasonably priced semiconductor profit stream.Hide full reasonI expect PLAB's $2.16 EPS at 13.48 times earnings to offer a reasonably priced semiconductor profit stream. The 6.82% twenty-session gain supplies secondary confirmation, but not a receivables audit. What would change the view: I'm wrong if later disclosures show weakening profitability or cash trapped in working capital; I keep the allocation below 3%. Original explanation and evidence referencesI expect PLAB's $2.16 EPS at 13.48 times earnings to offer a reasonably priced semiconductor profit stream [PLAB-E3]. The 6.82% twenty-session gain supplies secondary confirmation [PLAB-E5], but not a receivables audit. I'm wrong if later disclosures show weakening profitability or cash trapped in working capital; I keep the allocation below 3%. |
| MATXIncrease target | 2.65% | 2.7% | +0.05 pp | I expect MATX's $13.28 EPS at 17.71 times earnings to support measured compounding.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect MATX's $13.28 EPS at 17.71 times earnings to support measured compounding. The 1.42% twenty-session decline offers no compelling reason to rewrite the existing part of the portfolio. What would change the view: I'm wrong if subsequent disclosures show that cash generation cannot sustain reported profits; its higher multiple than the other shipping files limits sizing. Original explanation and evidence referencesI expect MATX's $13.28 EPS at 17.71 times earnings to support measured compounding [MATX-E4]. The 1.42% twenty-session decline offers no compelling reason to rewrite the existing sleeve [MATX-E6]. I'm wrong if subsequent disclosures show that cash generation cannot sustain reported profits; its higher multiple than the other shipping files limits sizing. |
| PLMRReduce target | 2.7% | 2.7% | 0 pp | I expect PLMR's $7.06 EPS at an 18.90 multiple to support earnings-backed appreciation.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: quartersI expect PLMR's $7.06 EPS at an 18.90 multiple to support earnings-backed appreciation. October 13 commentary reports recent earnings beats, useful corroboration but no substitute for reserve scrutiny. What would change the view: I'm wrong if later filings expose inadequate reserves or weaker recurring profits; I preserve a modest part of the portfolio rather than buy an earnings-surprise prediction. Original explanation and evidence referencesI expect PLMR's $7.06 EPS at an 18.90 multiple to support earnings-backed appreciation [PLMR-E4]. October 13 commentary reports recent earnings beats, useful corroboration but no substitute for reserve scrutiny [PLMR-E7]. I'm wrong if later filings expose inadequate reserves or weaker recurring profits; I preserve a modest sleeve rather than buy an earnings-surprise prediction. |
| ABMReduce target | 2.77% | 2.6% | -0.17 pp | I expect ABM's $2.88 EPS at 17.60 times earnings to support modest appreciation.Hide full reasonI expect ABM's $2.88 EPS at 17.60 times earnings to support modest appreciation. But October 13 commentary flags $1.8 billion borrowings and interest expense rising 13.2%. I trim current 2.77% and recent 2.80% intent to 2.60%. What would change the view: I'm wrong if financing costs overwhelm operating progress. Original explanation and evidence referencesI expect ABM's $2.88 EPS at 17.60 times earnings to support modest appreciation [ABM-E4]. But October 13 commentary flags $1.8 billion borrowings and interest expense rising 13.2% [ABM-E7]. I trim current 2.77% and recent 2.80% intent to 2.60%. I'm wrong if financing costs overwhelm operating progress. |
| EPAMReduce target | 2.63% | 2.5% | -0.13 pp | I expect EPAM's $6.96 EPS at 16.59 times earnings to furnish a foundation for recovery.Hide full reasonI expect EPAM's $6.96 EPS at 16.59 times earnings to furnish a foundation for recovery. The 6.49% twenty-session decline keeps my pencil cautious and allocation modest. What would change the view: I'm wrong if later reports show lasting earnings deterioration rather than temporary price weakness; I will not confuse a falling quote with proof. Original explanation and evidence referencesI expect EPAM's $6.96 EPS at 16.59 times earnings to furnish a foundation for recovery [EPAM-E3]. The 6.49% twenty-session decline keeps my pencil cautious and allocation modest [EPAM-E5]. I'm wrong if later reports show lasting earnings deterioration rather than temporary price weakness; I will not confuse a falling quote with proof. |
| AEOIncrease target | 1.94% | 2% | +0.06 pp | I expect AEO's 9.31 multiple on $1.91 EPS to retain some valuation support.Hide full reasonRecorded explanation · terminology clarified Conviction: medium · Horizon: monthsI expect AEO's 9.31 multiple on $1.91 EPS to retain some valuation support. October 13 commentary flags quarterly EPS declining 7.55%, despite the strong tape. I preserve the current near-2% part of the portfolio and recent 2% intent. What would change the view: I'm wrong if earnings erosion strips away the apparent discount. Original explanation and evidence referencesI expect AEO's 9.31 multiple on $1.91 EPS to retain some valuation support [AEO-E4]. October 13 commentary flags quarterly EPS declining 7.55%, despite the strong tape [AEO-E6]. I preserve the current near-2% sleeve and recent 2% intent. I'm wrong if earnings erosion strips away the apparent discount. |
| DXCIncrease target | 1.73% | 1.8% | +0.07 pp | I expect DXC's 7.83 multiple on $1.63 EPS to support an earnings-led rerating.Hide full reasonI expect DXC's 7.83 multiple on $1.63 EPS to support an earnings-led rerating. The 6.06% twenty-session advance is corroboration, not permission to enlarge yesterday's small target. What would change the view: I'm wrong if later filings reveal that reported profit fails to translate into recurring cash; the position remains a restrained recovery file. Original explanation and evidence referencesI expect DXC's 7.83 multiple on $1.63 EPS to support an earnings-led rerating [DXC-E3]. The 6.06% twenty-session advance is corroboration, not permission to enlarge yesterday's small target [DXC-E5]. I'm wrong if later filings reveal that reported profit fails to translate into recurring cash; the position remains a restrained recovery file. |
| KSSIncrease target | 1.78% | 1.8% | +0.02 pp | I expect KSS's $2.57 EPS at 8.21 times earnings to retain a modest value opportunity.Hide full reasonI expect KSS's $2.57 EPS at 8.21 times earnings to retain a modest value opportunity. The 28.97% twenty-session gain is emphatic price confirmation, not evidence that inventory and liabilities are clean. What would change the view: I'm wrong if subsequent filings show profit deterioration; I keep this fast-moving file at only 1.80%. Original explanation and evidence referencesI expect KSS's $2.57 EPS at 8.21 times earnings to retain a modest value opportunity [KSS-E4]. The 28.97% twenty-session gain is emphatic price confirmation, not evidence that inventory and liabilities are clean [KSS-E6]. I'm wrong if subsequent filings show profit deterioration; I keep this fast-moving file at only 1.80%. |
Portfolio checks
The complete proposal passed the versioned universe, cash, concentration, and posture constraints without platform modification.
These checks cover portfolio constraints. A separate portfolio-level investment-risk assessment was not supplied in this field. Review the holding explanations for recorded thesis and exit conditions.
Ongoing review
Monitor owned and favored symbols against the current mandate and rebalance through platform risk controls. Each speculative position is capped. Monitor for volatility spikes and reduce if concentration limits are approached.
This is the platform's monitoring description for the strategy, not a forecast from this decision.
Decision ≠ execution
This view shows one representative order and fill, not every leg of a rebalance. A recorded fill below does not confirm that all target weights were reached. Open the strategy portfolio to inspect current holdings.
Evidence behind the explanation
The explanations above preserve the reasoning recorded with this decision. The record details below show processing and execution history. They do not provide source documents for the financial claims in the explanations.
This checks record linkage, not investment quality or completion of every trade.
These identify processing inputs and validation steps. They are not linked research sources.
Small-Cap Fundamentals cycle started by scheduled.
Small-Cap Fundamentals produced a canonical target-weight decision.
Small-Cap Fundamentals cycle completed with status no_action; elapsedMs=88692.
Small-Cap Fundamentals valuation snapshot recorded for agent_cycle_run 01M4X3RBEXXTEW1KZY7Z90K96P.
